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Abstract
Background: Little is known about the clinical presentation and outcomes amongst older HIV infected populations
accessing ART in sub-Saharan Africa. We compared mortality amongst HIV infected patients accessing ART that
were < 50 years to those ≥50 years in Kwa-Zulu Natal, South Africa.
Methods: We undertook a retrospective review of medical records of patients that accessed HIV services at the
CAPRISA AIDS Treatment program (CAT) between June 2004 to December 2012 (N = 4003). HIV infected patients,
14 years or older were enrolled. All-cause mortality and treatment response to ART in those < 50 years to those
≥50 years were compared. A Kaplan-Meier curve and log-rank test were used to compare the cumulative
probability of death between the two age groups with the primary endpoint being mortality. Statistical analysis was
done using SAS (version 9.4.; SAS Institute Inc., Cary, NC, USA).
Results: Of 4003 individuals, 262 (6.5%) were ≥ 50 years (older group). The median age in those ≥50 years and
< 50 year was 54.5 and 32.0 years, respectively. The younger group was mainly female (64.7%). There was no
difference in mortality rate, between the older (6.9/100 person-years (py), 95% confidence interval (CI): 4.7–9.6) and
younger group (5.3/100 py, 95% CI: 4.7–5.8) at 60 months (p = 0.137). In the multivariable model older patients had
a significantly higher risk of death compared to younger patients. (hazard ratio (HR) 1.60, 95% CI: 1.08–2.39, p = 0.
019).The rate of CD4+ cell count increase was higher in those < 50 years (β = 0.34, 95% CI: 0.19–0.50, p < 0.001) with
no difference in viral suppression. The older group showed significantly higher prevalence of diabetes (6.3%) and
hypertension (21.5%), p < 0.001.
Conclusion: ART initiation in older HIV infected patients was associated with a higher mortality compared to those
younger than 50 years. ART immunological response was less robust in older individuals. The increase in
hypertension and diabetes among older patients suggests the need to restructure and integrate primary and
specialized health care services into ART services.
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Background
In 2015, there were approximately 36.7 million people
living with human immunodeficiency virus (HIV) [1].
North American and European HIV treatment cohorts
have demonstrated good clinical outcomes among older
individuals initiating antiretroviral treatment (ART)
[2, 3]. However, an increase in long-term treatment
adverse events and non-HIV related disease has been
reported [4]. The ATHENA (AIDS Therapy Evaluation
in The Netherlands) cohort in Netherlands compris-
ing 10,000 patients on ART with a median age of
44 years, has postulated that the proportion of HIV-
infected patients 50 years and older will increase from
28% in 2010 to 73% in 2030, [5] by which time the
median age of patients will increase to 56.6 years [5].
South Africa had approximately 6.4 million HIV in-
fected people in 2012 accounting for 17% of the global
burden of HIV infection [6]. It is anticipated that the
successes in HIV treatment and prevention over the past
decade in South Africa and Sub-Saharan Africa attribut-
able to the rapid expansion of ART access, stabilizing
HIV sero-prevalence and increase in life expectancy
from 52 years in 2003 to 61 years 2011, will create a
demographic shift of those in HIV care [7].
Specifically an increased number of HIV infected pa-
tients surviving to older age groups. Indeed, the number
of adults over the age of 60 years in Africa is projected
to rise by 55% between 2010 and 2025, a 135% increase
since 1995 [8, 9]. It is estimated that by 2050, approxi-
mately 15% of the total South African population will be
60 years or older [10]. Recent South African HIV sero-
prevalence studies among patients ≥50 years report HIV
prevalence rates of 7.6% (95% CI 6.5–8.8) in 2012 [6].
Current ART use has contributed to a dramatic reduction
in opportunistic infection incidence [11]. However, as the
median age of those on ART increases, the clinical course
of HIV disease is likely to differ in older individuals com-
pared to younger patients. While, better ART adherence
and good virologic response has been demonstrated in
those ≥50 years, studies have also showed significantly
slower immunologic recovery among older patients
[12, 13]. In the United States older HIV infected indi-
viduals are at an increased risk for co-morbidities associ-
ated with life-style, aging and complications of long term
ART use such as hypertension, diabetes, and renal impair-
ment [14]. Treatment of HIV in older patients in Sub-
Saharan Africa is poorly understood largely as limited
resources are currently directed at scaling up services for
pregnant women, children, and young adults [15]. The
HIV infected aging population in Sub Saharan Africa will
continue to grow, thus there is a critical need to under-
stand HIV and ART related co- morbidities and outcomes
in these patients to enable resources for early identifica-
tion and prompt and appropriate management.
We conducted a retrospective data review of patients
enrolled and followed up prospectively on ART at the
Center for AIDS Programme of Research in South Africa
(CAPRISA) AIDS treatment (CAT) programme between
2004 and 2012 and aimed to compare survival and treat-
ment outcomes of patients < 50 years to those ≥50 years
in Kwa-Zulu Natal, South Africa.
Methods
Study design and participants
Study patients, design and setting
The CAPRISA Acquired immunodeficiency syndrome
(AIDS) treatment program (CAT) was a prospective
treatment cohort, which enrolled patients between June
2004 to December 2012 (N = 4006) at two treatment
sites, the CAPRISA eThekwini clinical research site
(urban) adjacent to the Prince Cyril Zulu Communicable
Disease Centre (PCZCDC), in Durban, and the Vulin-
dlela site, (rural), in KwaZulu-Natal. Details of the co-
hort, procedures and the primary outcomes of the
cohort have been described previously [16]. ART-naïve
patients, 14 years and older, who initiated standard first-
line ART (two nucleoside reverse transcriptase inhibitors
and a non-nucleoside reverse transcriptase inhibitor)
between June 2004 and December 2012 as per current
national guidelines [17, 18], were included in this analysis.
In 2004 the eligibility to initiate ART was a CD4+ count of
less than 200 cells/mm3 or an AIDS defining illness. The
CD4+ count threshold was increased to ≤350 cells/mm3 for
pregnant women and any CD4+ count level for those with
TB co-infection in 2010. Finally, in 2012 the CD4+ count
threshold was increased to ≤350 cells/mm3. Inadditon, all
pregnant women irrespective of CD4 + cell count level
were eligible for ART initiation in 2012 [17].
HIV-infection was confirmed by two successive rapid
HIV Enzyme linked immunoabsorbent assay (ELISA)
tests. Loss to follow-up was defined as missing three or
more consecutive scheduled visits and where attempts
to locate the patient in the community failed. Death was
ascertained through telephonic or physical tracking of
patients and confirmed by family members.
Study procedures
ART eligibility and treatment guidelines followed the
existing national guidelines that prevailed [17]. Patient
information including demographic information, detailed
medical history and a full evaluation of the current
clinical condition was undertaken at screening, ART en-
rolment and initially monthly for the first 6 months post-
ART initiation, then every 2–3 months, unless clinically in-
dicated. Routine safety laboratory tests and CD4+ counts
(FACS flow cytometer: Becton Dickinson, Franklin Lakes
NJ, USA) and viral loads (Roche Cobas Amplicor HIV-1
Monitor v1.5) were done at baseline and six-monthly.
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These details, along with details of intercurrent illnesses
and medication prescribed, were captured in real-time on
case report form (CRF) templates and submitted to a
central CAPRISA electronic data management system
(Clinical DataFax Systems Inc., Ontario, Canada). Queries
arising during validation of the data were recorded in qual-
ity control reports sent to the sites on a regular basis. All
patients received standard of care as per national depart-
ment of health guidelines [17].
Virologic failure was defined as a viral load > 1000
copies/ml detected on two occasions, taken at least
4 weeks apart, and resulted in complete regimen change.
Viral suppression or undetectable viral load was defined
as a viral load of < 400 copies/ml. Those with a viral load
below 1000 but ≥400 copies/ml were not considered as
virological failure requiring complete ART regimen
change.
Hypertension was defined as a blood pressure (BP) of
140 mmHg or more systolic or a diastolic BP of
90 mmHg or more at the time of ART initiation. Pa-
tients already on medication for hypertension were con-
sidered to be hypertensive. Patients were classified as
diabetic if they had a fasting plasma glucose of 7 mmol/l
(126 mg/dL) or random plasma glucose > 11.1 mmol/l
(200 mg/dL) or if on insulin or any oral hypoglycemic
agent at the time of ART initiation.
Ethics and consent
Ethics approval for use of the treatment program data was
obtained from the Biomedical Research Ethics Committee
of the University of KwaZulu-Natal.(Ref-E248/05). The
biomedical research ethics committee reviewed the appli-
cation and deemed the need for consent unnecessary in
terms of national regulations: “the REC may approve a
waiver of consent for secondary use of material or data
where no more than minimal risk of harm is likely; and
donor rights and welfare interests are unlikely to adversely
affected; and research cannot be conducted if waiver is not
approved”.Informed consent was obtained for HIV testing
and treatment (including those less than 16 years) from all
individuals included in the study in keeping with standard
of care [18]. The national health Act permitted children
12 years and older to access HIV care without parental or
guardian consent. Hence no parental or guardian consent
was required for this age group [18].
Statistical analysis
This analysis included all patients 14 years and older
who were followed-up for a maximum of 60 months
post ART initiation. Analysis was stratified by age at
ART initiation, < 50 years [younger] and ≥ 50 years
[older]. Demographic and clinical variables were summa-
rized using median with interquartile range (IQR), mean
with standard deviation and percentages. All statistical
tests were two sided. Fisher’s exact test was used for the
analysis of categorical data. The t-test for independent
samples or Wilcoxon two-sample test was used for the
analysis of continuous data.
Linear mixed model was used to determine the differ-
ence in rate of increase in CD4+ cell count between the
two age groups. Square root transformation was used to
achieve CD4+ cell count normality.
A Kaplan-Meier curve and log-rank test were used to
compare the cumulative probability of death between
the two age groups with the primary endpoint being
mortality. Censorship was at the earliest recorded date
of death, date of loss to follow-up or date of transfer out
of the cohort. Poisson approximations were used to
calculate confidence intervals (CIs) for mortality rates.
Univariate and multivariate proportional hazards regres-
sion models were used to assess predictors of mortality.
Multivariable models were adjusted for the following
baseline covariates: gender, clinic site, CD4+ cell count,
body mass index (BMI), World Health Organisation
(WHO) stage, diabetes status, hypertension status, past
history of tuberculosis (TB) and current tuberculosis dis-
ease. Proportionality was assessed by fitting time
dependent covariates in a model created by interacting
baseline variables with survival time. All-cause mortality
was assessed. Statistical analysis was done using SAS
(version 9.4.; SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
A total of 4003 individuals initiated antiretroviral treat-
ment (ART) between June 2004 and December 2012; 6.
5% were 50 years and older (older group). The baseline
demographic characteristics of the two groups are illus-
trated in Table 1. The median age at ART initiation in
the older group was 54.5 years (interquartile range
(IQR): 52–58 years) in comparison to 32.0 years (IQR:
28–38 years) in the younger group. The median duration
of follow up for the cohort was 16.2 months (IQR: 8.0–
34.9 months). The follow up of participants over time is
reflected in Additional file 1: Figure S1.
There was no significant difference between the
groups overall in terms of body mass index, baseline
viral load, WHO clinical stage or current or past history
of TB. Gender distribution between the groups varied,
with the younger group comprising 64.7% female com-
pared to 55.3% in the older group, p = 0.003.There were
28 pregnant women in this cohort. More older individ-
uals (62.2%) was found in the rural site compared to 54.
8%, in the urban site, (p = 0.021). Most patients in both
groups presented with WHO clinical stage 3 or 4 disease
prior to initiating ART. A significantly higher prevalence
of diabetes (6.3%) and hypertension (21.5%) was ob-
served in the older group (p < 0.001), Table 1.
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Overall, approximately 73% of patients presented
with a baseline CD4+ cell count of < 200 cells/mm3,
with older patients demonstrating a significantly
higher median baseline CD4+ cell count compared to
younger patients,142 vs.124 cells/mm3, p = 0.001 (Table 1).
The changes in baseline CD4+ cell count thresholds
at different years of ART initiation is illustrated in
Additional file 1: Figure S2.
Response to ART
The rate of CD4+ cell count increase was significantly
higher in patients < 50 years old (β = 0.345, 95% CI 0.
189–0.4500, p < 0.001) compared to those > 50 years,
Fig. 1, Additional file 2: Table S3. This trend persisted
after adjusting for baseline covariates (β = 0.34 95% CI 0.
18–0.50, p < 0 .001). The proportion of individuals that
achieved virologic suppression during follow-up did not
differ between the groups, (Fig. 1). At the end of follow-
up there were 15/357(4.2%) individuals in the younger
group and none in the older group with a CD4 + cell
count < 200 cells/μl. None of the older patients experi-
enced virological failure whilst 0.4% of the younger
group required a change of ART treatment regimen due
to first regimen virologic failure.
Mortality
There were a total of 403 deaths in the study at 60 months,
with 8.2% of all deaths belonging to patients in the older
group and 91.8% among patients in the younger group.
The mortality rate was 6.7 per 100 person-years (py) (95%
confidence interval (CI): 4.6–9.4) in the older group and 5.1
per 100 person-years (95% CI: 4.6–5.7) (p = 0.137) (Fig. 2)
in the younger group. Most patients died within the first
24 months of follow-up (Fig. 2). The probability of death
was similar at 6,12 and 24 months between the groups,
however, between 24 months and 60 months the probabil-
ity of death was higher in the older group, 6.7 vs 5.1 per
100 person years, respectively, p = 0.137 (Fig. 2, Additional
file 1: Figure S3). While the cause of death in the majority
Table 1 Baseline and demographic characteristics of individuals
(n = 4003) older and younger with HIV infection on antiretroviral








Year of entry –
2004 2 (0.8) 74 (2.0)
2005 34 (13.0) 568 (15.2)
2006 39 (14.9) 574 (15.3)
2007 18 (6.9) 270 (7.2)
2008 11 (4.2) 181 (4.8)
2009 34 (13.0) 369 (9.9)
2010 60 (22.9) 877 (23.4)
2011 54 (20.6) 655 (17.5)
2012 10 (3.8) 173 (4.6)
Age (years), median (IQR) 54. 5 (52–58) 32 (28–38) –
Gender, n (%)
Male 117 (44.7) 1321 (35.3) 0.003
Female 145 (55.3) 2420 (64.7)
Clinic site, n (%) 0.021
Urban 99 (37.8) 1691 (45.2)
Rural 163 (62.2) 2050 (54.8)
Median body mass index
(kg/m2), (IQR)a
23.1 (20.5–27.1) 22.8 (20.2–26.4) 0.154
Baseline CD4+ count,
(cells/μl) median(IQR)b




< 200 173 (76.5) 2747 (81.2)
200–350 45 (19.9) 568 (16.8)
> 350 8 (3.5) 70 (2.1)
Viral load (log copies/ml),
mean (SD)e
4.9 (1.0) 5.0 (0.9) 0.268
WHO stage, n (%)c 0.623
1 40 (15.3) 556 (14.9)
2 60 (22.9) 744 (20.0)
3 131 (50.0) 2004 (53.8)
4 31 (11.8) 424 (11.4)
Past history of TB, n (%)d 62 (24.2) 1077 (29.5) 0.075
Prevalent TB, n (%) 62 (23.7) 907 (24.2) 0.882
Co-morbidities
Hypertensione 55 (21.5) 79 (2.2) <.001
Diabetesf 16 (6.3) 24 (0.7) <.001
Occupationg 0.014
Employed 83 (32.2) 1193 (32.3)
Unemployed 156 (60.5) 2358 (63.9)
Scholar/Other 19 (7.4) 137 (3.7)
Table 1 Baseline and demographic characteristics of individuals
(n = 4003) older and younger with HIV infection on antiretroviral









2NRTI + NNRTI 260 (100%) 3718 (99.6%)
2NRTI + PI 0 15 (0.4%)
a221 missing BMI (8 older, 213 younger), b392 missing CD4 count(36 older, 356
younger), c13 younger missing WHO stage, d102 missing past history of TB (6
older,96 younger), e475 missing viral load (34 older,441 younger), e96 missing
hypertension (6 older,90 younger), f96 missing diabetes (6 older,90 younger),
g57 missing occupation(4 older, 53 older)
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of cases, was unknown, where a cause of death was estab-
lished, the proportion of non HIV/TB associated deaths
was higher in those 50 years and older. (Additional file 2:
Table S1).Two-thirds of the known causes of death in those
less than 50 years were associated with HIV with or without
TB, while only 6% of deaths in those 50 years and older
were reported to be HIV/TB associated.
Age group was not associated with mortality in the
univariate model. In the multivariable model older pa-
tients had a significantly higher risk of death compared
to younger patients. (hazard ratio (HR) 1.60, 95% CI: 1.
08–2.39, p = 0.019). An increase in CD4+ cell count and
body mass index was associated with a decline in the
risk of mortality.
Other variables associated with a higher risk of mortal-
ity included low BMI, and WHO stage 3 and 4 disease, a
diagnosis of prevalent diabetes and the absence of preva-
lent TB at ART initiation. WHO clinical stage 4 was
associated with a fourfold risk of mortality. These factors
together with male gender and hypertension were sig-
nificant in the sensitivity analysis (Table 3) that assumed
that all patients lost to follow up had died (Table 2).
Discussion
In this prospective, observational cohort comparing out-
comes of HIV infected individuals among patients
50 years and older to those younger than 50 years, we
observed a higher mortality in the older compared to
Fig. 1 Mean CD4+ count over with 95% CI and proportion with undetectable viral load
Fig. 2 Kaplan-Meier estimates of cumulative probability of death for patients exposed to ART according to age groups
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those younger than 50 years following 60 months of
treatment. Unsurprisingly, most deaths occurred in the
first 24 months post ART initiation. The mortality in the
first 12 months did not differ significantly in both
groups and is in keeping with other reports from sub Sa-
haran Africa where high mortality is reported following
initial initiation of ART [19].
Cause of death, where established was found to be not
related to HIV or TB in the vast majority of patients
older than 50 years of age in our study. Conversely, al-
most two-thirds of all deaths were found to be associ-
ated to either TB and/or HIV among patients that were
less than 50 years old. These findings illustrate the bene-
fit of ART in protecting against AIDS related morbidity
and mortality over time. Furthermore, older patients had
an overall higher prevalence of co-morbidity such as
hypertension and diabetes at ART initiation [20].
We found that irrespective of age, men were more likely
to die within the ART programme compared to women.
This however may, in part, be reflecting the epidemiology
of HIV in Sub-Saharan Africa. Here women acquire HIV
at a younger age and enroll in ART programs earlier in
the course of their disease through enhanced contact with
health care services that traditionally offer an entry point
into the HIV care continuum such as sexual reproductive
health services, antenatal and perinatal services [21]. This
difference in mortality outcomes by gender has been
demonstrated previously in a rural South African setting,
however the data presented was limited to pre-ART and 1
year post ART initiation outcomes only [7]. Similarly,
prevalent TB also previously shown to be associated with
a low mortality, maybe related to TB care being an access
point to earlier ART initiation.
Our study also demonstrated that patients ≥50 years
demonstrated poorer immununologic recovery on ART,
as shown by poorer CD4+ cell count recovery, compared
to younger patients. The slow CD4+ cell count recovery
in our older cohort is consistent with other studies
which indicate that older individuals have a lower rate of
increase in CD4+ cell counts following ART exposure
compared to younger individuals [22]. This ability to in-
crease CD4 cell count determined the risk of death in
the multivariable model [23, 24]. The risk of death was
associated with CD4++ cell count. Without CD4+ cell
count in the model the difference in risk of death be-
tween the older and younger group was insignificant and
hence CD4 + cell count at ART initiation is an important
predictor of mortality in those ≥50 years.
Traditional age related co-morbidities appear to occur
earlier in older HIV infected patients compared to HIV
uninfected counterparts of the same age [14]. We saw a
ten-fold increased prevalence of hypertension and dia-
betes in the older compared to younger cohort. Co -
morbidities such as hypertension and diabetes were
more prevalent in the older group and this may reflect
an increased likelihood of contact with health care ser-
vices and thus earlier initiation of ART in accordance
with HIV treatment guidelines. However, the risk of co-
morbidities increases as individuals get older, and there
is a need to modify antiretroviral treatment to ensure a
minimum impact on these comorbidities [14].
At baseline we noted a nine fold increase in prevalent
diabetes in older patients in comparison to the younger
cohort and a similar trend in hypertension prevalence.
(Table 3). A recent study in KwaZulu Natal estimated
the crude prevalence of diabetes to be 12.5% and this is
higher than the national prevalence of 9,2% [25]. This
high prevalence is reflected in this HIV infected cohort.
Whilst the prevalence of hypertension and diabetes
appear to be lower than the general population, this co-
hort illustrates the opportunity that HIV treatment pro-
vides for comprehensive multi-morbidity care in Sub
Saharan Africa.A similar prevalence was found in a
Malawi cohort [26]. Presenting for HIV care enables
screening and early detection and treatment for hyper-
tension and diabetes.
The strategies of anti-retroviral therapy (SMART) and
evaluation of subcutaneous Proleukein ® in randomized
International trial (ESPIRIT) trials demonstrated that
the frequency of Non-AIDS events was approximately
50% higher than AIDS events and the mortality of non
AIDS events were double that of AIDS events [27]. In
this cohort the prevalence of TB was similar to hyper-
tension at baseline in the older cohort compared to the
younger cohort. The prevalence of hypertension and dia-
betes was much lower than the prevalence of TB (> 10
times) in the younger cohort indicating that the focus of
screening in the different age groups may be different
over the life course of treatment of HIV infection [28].
Limitations
This study has the advantage of a large sample size;
however, survival bias may have resulted in patients with
a better prognosis entering the cohort especially in the
older group. Furthermore, the proportion of those older
than 50 years was smaller than those in the younger
group. This disproportion may have further contributed








Died 33 (12.6) 370 (9.9) 0.167
Transferred out 203 (77.5) 2850 (76.2) 0.653
Relocated 2 (0.8) 51 (1.4) 0.580
Defaulted/stopped ART 23 (8.8) 458 (12.2) 0.115
Othera 1 (0.4) 12 (0.3) 0.586
a3 were in jail and 8 reasons unknown
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to bias. Furthermore, the change in ART eligibility guide-
lines and CD4+ cell counts (Additional file 1: Figure S2)
over the follow up time likely contributed to a time
dependent bias. Missing data as listed in Table 1 may have
contributed to bias but the sensitivity analysis (Table 3)
did not show any significant changes in the predictors of
mortality. Whilst the enrollment into the treatment cohort
was between 2004 to 2012, participants exited to facilities
nearer their homes during follow up, hence not all partici-
pants were followed up for the entire study duration. The
median time for transfer out of the cohort was 2 years
(IQR:1 to 3 years). Furthermore, missing data for parame-
ters of renal function, causes of death and ART adverse
events limits a more in-depth analysis of co-morbidities
and its association with survival and ART outcomes in the
older cohort [29].
Conclusion
We demonstrate that following ART initiation, older
HIV infected Africans had a higher mortality compared
to those younger than 50 years. Response to ART treat-
ment in terms of virological response is similar to youn-
ger individuals on ART; however the immunological
response is less robust in older individuals. This cohort
highlights the need for multi-morbidity management
and the benefits of ART over time.. Further studies are
required to determine the causes of mortality in those
older than 50 years and the long term effect of ART on
Table 3 Predictors of all-cause mortality
Variable at ART initiation Original analyses Sensitivity analysesa
Univariate Multivariate Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Group
< 50 years 1.0 1.0 1.0 1.0
≥ 50 years 1.29 (0.91–1.85) 0.157 1.60 (1.08–2.39) 0.019 0.98 (0.75–1.29) 0.908 1.07 (0.79–1.44) 0.652
Gender
Male 1.0 1.0 1.0 1.0
Female 1.42 (1.16–1.73) <.001 1.14 (0.91–1.44) 0.242 1.41 (1.23–1.61) <.001 1.31 (1.12–1.53) <.001
Site
Urban 1.0 1.0 1.0 1.0
Rural 1.24 (1.01–1.53) 0.043 1.20 (0.94–1.53) 0.147 1.53(1.32–1.78) <.001 1.49 (1.25–1.78) <.001
CD4+ count
(per 50 cells/mm3 increase)
0.73 (0.67–0.78) <.001 0.78 (0.72–0.84) <.001 0.90 (0.86–0.94) <.001 0.93 (0.89–0.98) 0.003
Body mass index (per 5 kg/m2 increase) 0.66 (0.58–0.74) <.001 0.76 (0.66–0.87) <.001 0.77(0.71–0.83) <.001 0.84 (0.77–0.91) <.001
WHO stage
Stage 1 1.0 1.0 1.0 1.0
Stage 2 1.50 (0.94–2.40) 0.091 1.49 (0.89–2.48) 0.129 0.83 (0.65–1.06) 0.14 0.84 (0.64–1.10) 0.212
Stage 3 2.47(1.65–3.71) <.001 2.12 (1.34–3.36) 0.001 1.15 (0.94–1.40) 0.181 1.18 (0.93–1.49) 0.172
Stage 4 5.01 (3.23–7.75) <.001 4.18 (2.51–6.95) <.001 1.62 (1.26–2.07) <.001 1.72 (1.28–2.32) <.001
Presented with diabetes
No 1.0 1.0 1.0 1.0
Yes 1.55 (0.69–3.48) 0.286 2.67 (1.16–6.14) 0.021 1.08 (0.56–2.08) 0.821 1.83 (0.94–3.60) 0.077
Presented with hypertension
No 1.0 1.0 1.0 1.0
Yes 0.50 (0.24–1.05) 0.067 0.57 (0.26–1.24) 0.158 0.51 (0.31–0.84) 0.008 0.58 (0.34–1.00) 0.049
Past history of TB
Yes 1.23 (1.00–1.52) 0.051 0.89 (0.70–1.12) 0.323 1.03 (0.89–1.19) 0.732 0.91 (0.78–1.08) 0.291
No 1.0 1.0 1.0 1.0
Prevalent TB
Yes 1.0 1.0 1.0 1.0
No 1.24 (0.98–1.64) 0.068 1.82 (1.34–2.45) <.001 1.23 (1.03–1.46) 0.020 1.41 (1.15–1.75) 0.001
aAssuming all patients who were loss to follow-up died
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co-morbidities and pharmacokinetics of ART in those
50 years and older to optimize long term safety. In
addition, the impact of convergence of non-communicable
diseases, HIV infection, chronic ART and ageing in this
population in the long term needs to be evaluated. The in-
crease in medical co-morbidities will require co-ordination
and restructuring of primary and specialized care services
in this vulnerable population and may require a different
integrated model of care.
Additional files
Additional file 1: Figure S1. Flow diagram of cumulative participant
attrition over 6 years following enrolment into the CAPRISA Acquired
immunodeficiency syndrome (AIDS) treatment program (CAT) with HIV
infection on antiretroviral treatment (ART) from June 2004 to December
2012. Figure S2. CD4+ count at ART initiation at different years of
enrolment reflecting time dependent bias of increasing CD4+ count
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